Developmental Therapeutics Program
Developmental Therapeutics Program
批准号:
10174774
负责人:
Steven Grant
金额:
$8.73万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-12-01 至 2023-04-30
关键词:
Antineoplastic AgentsBasic ScienceCancer BiologyCancer CenterCancer Center Support GrantCharacteristicsClinicalClinical ResearchComputational BiologyDevelopmental Therapeutics ProgramDirect CostsDiseaseDrug CombinationsDrug DesignDrug resistanceEvaluationFundingGoalsHematologic NeoplasmsHumanLaboratoriesMalignant NeoplasmsMolecularNew AgentsOutcomePathway interactionsPatient-Focused OutcomesPatientsPeer ReviewPharmaceutical PreparationsPharmacodynamicsPhasePhase I/II TrialPhase III Clinical TrialsPublicationsRegimenResearchResistanceSchoolsSolid NeoplasmTherapeuticTherapeutic AgentsTherapeutic InterventionTranslatingTreatment EfficacyUnderserved PopulationUniversitiesVirginiaWorkaddictionbasebiomarker identificationcancer celldesignearly phase clinical trialfirst-in-humanimprovedimproved outcomeinnovationinsightinvestigator-initiated trialmemberneoplastic cellnovelpreclinical studyprogramsstructural biologytargeted agenttrial design
中文摘要
药物治疗:项目
总结/摘要
发展治疗学(DT)计划的目标是开发新的见解,
新的和已建立的抗癌药物的作用机制,并利用这些发现,通过翻译
以创新的I期和II期试验的形式将其引入临床竞技场。该计划的科学目标是
(1)阐明新的和现有的治疗剂和方法的作用机制,并寻求
基于癌症生物学中有希望的发现的有益治疗干预的机会
来自DT计划和其他弗吉尼亚联邦大学梅西癌症中心(MCC)
方案;(2)制定能够克服人类恶性肿瘤对单一药物耐药性的策略
通过设计合理的药物组合,避免多重代偿,
癌细胞的生存途径特征;和(3)推进新兴概念的治疗,
将人类癌症纳入早期临床试验,重点关注DT项目成员提出的概念
实验室以及其他MCC计划。为了推进这些目标,该计划的研究已经
已组织成4个相互关联的主题,目标是最大限度地提高方案内和方案间的成果
交互.这些研究主题包括:(1)结构和计算生物学与药物设计;(2)
涉及新药和现有药物的作用机制研究;(3)靶向药物的合理组合,
临床和临床前研究;以及(4)将新兴策略转化为研究者-
启动试验。DT计划有43名成员,代表13个部门和3所学校。DT计划
与癌症相关的资金总额为620万美元(同行评审的直接费用为500万美元),其中240万美元是
100万是NCI的。在2011-2015年期间,DT计划共发表了696篇文章,其中22%
24%是项目内的,24%是项目间的。
英文摘要
DEVELOPMENTAL THERAPEUTICS PROGRAM: PROJECT
SUMMARY/ABSTRACT
The objectives of the Developmental Therapeutics (DT) program are to develop new insights in to the
mechanisms of action of new and established anti-cancer agents, and to exploit these findings by translating
them into the clinical arena in the form of innovative phase I and II trials. The scientific goals of the program are
to: (1) elucidate the mechanisms of action of new and existing therapeutic agents and approaches, and to seek
opportunities for beneficial therapeutic interventions based upon promising discoveries in cancer biology
emanating from the DT program and other Virginia Commonwealth University Massey Cancer Center (MCC)
programs; (2) develop strategies capable of overcoming drug resistance of human malignancies to single
targeted agents through the design of rational drug combinations that circumvent multiple compensatory
survival pathways characteristic of cancer cells; and (3) advance emerging concepts for the treatment of
human cancers into early-phase clinical trials, focusing on concepts emanating from DT program member
laboratories as well as those of other MCC programs. To advance these goals, research in the program has
been organized into 4 interdigitating themes with the goal of maximizing fruitful intra- and interprogrammatic
interactions. These research themes include: (1) structural and computational biology and drug design; (2)
mechanism-of-action studies involving new and existing drugs; (3) rational combinations of targeted agents in
clinical and preclinical studies; and (4) translational implementation of emerging strategies into investigator-
initiated trials. The DT program has 43 members representing 13 departments and 3 schools. The DT program
has a total cancer-related funding base of $6.2 million ($5 million in peer-reviewed direct costs), of which $2.4
million was from the NCI. During 2011-2015, the DT program had a total of 696 publications, of which 22%
were intraprogrammatic and 24% were interprogrammatic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Princess Margaret Phase I Consorium (PMP1C)
-
批准号:9762723
-
项目类别:
-
资助金额:$34.14万
-
财政年份:2018
-
负责人:Steven Grant
-
依托单位:
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors
-
批准号:9252428
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2016
-
负责人:Steven Grant
-
依托单位:
Targeting Multiple Myeloma with Smac-mimetics and HDAC Inhibitors
-
批准号:9892981
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2016
-
负责人:Steven Grant
-
依托单位:
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics
-
批准号:8446728
-
项目类别:
-
资助金额:$28.43万
-
财政年份:2013
-
负责人:Steven Grant
-
依托单位:
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics
-
批准号:9195615
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2013
-
负责人:Steven Grant
-
依托单位:
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics
-
批准号:8785103
-
项目类别:
-
资助金额:$46.15万
-
财政年份:2013
-
负责人:Steven Grant
-
依托单位:
Targeting AML with PI3K/AKT inhibitors and BH3-mimetics
-
批准号:8605177
-
项目类别:
-
资助金额:$27.63万
-
财政年份:2013
-
负责人:Steven Grant
-
依托单位:
Proteasome/HDAC Inhibition in Leukemia/MDS; Phase I Trial and Correlative Studies
-
批准号:7944168
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2009
-
负责人:Steven Grant
-
依托单位:
Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma
-
批准号:7742109
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2009
-
负责人:Steven Grant
-
依托单位:
CLINICAL TRIAL: PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRI
-
批准号:8166543
-
项目类别:
-
资助金额:$0.58万
-
财政年份:2009
-
负责人:Steven Grant
-
依托单位:
PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS
-
批准号:8166530
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2009
-
负责人:Steven Grant
-
依托单位:
Proteasome/HDAC Inhibition in Leukemia/MDS; Phase I Trial and Correlative Studies
-
批准号:7853927
-
项目类别:
-
资助金额:$59.2万
-
财政年份:2009
-
负责人:Steven Grant
-
依托单位:
CLINICAL TRIAL: PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CE
-
批准号:7950855
-
项目类别:
-
资助金额:$12.04万
-
财政年份:2008
-
负责人:Steven Grant
-
依托单位:
CLINICAL TRIAL: PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRI
-
批准号:7950871
-
项目类别:
-
资助金额:$12.55万
-
财政年份:2008
-
负责人:Steven Grant
-
依托单位:
CLINICAL TRIAL: PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CE
-
批准号:7717023
-
项目类别:
-
资助金额:$5.5万
-
财政年份:2007
-
负责人:Steven Grant
-
依托单位:
CLINICAL TRIAL: PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRI
-
批准号:7717044
-
项目类别:
-
资助金额:$7.17万
-
财政年份:2007
-
负责人:Steven Grant
-
依托单位:
PHASE I TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH FLAVOPIRIDOL IN PATIENTS
-
批准号:7605038
-
项目类别:
-
资助金额:$4.07万
-
财政年份:2006
-
负责人:Steven Grant
-
依托单位:
PHASE I TRIAL OF BORTEZOMIB AND FLAVOPIRIDOL WITH RECURRENT B-CELL NEOPLASMS
-
批准号:7605011
-
项目类别:
-
资助金额:$4.49万
-
财政年份:2006
-
负责人:Steven Grant
-
依托单位:
PHASE I STUDY OF FLAVOPIRIDOL WITH IMATINIB MESYLATE (STI1571, GLEEVEC)
-
批准号:7605004
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2006
-
负责人:Steven Grant
-
依托单位:
CDK/histone deacetylase inhibition in acute leukemia
-
批准号:6944100
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2005
-
负责人:Steven Grant
-
依托单位:
海外基金